1
|
Alexandrov V, Vilenchik M, Kantidze O, Tsutskiridze N, Kharchilava D, Lhewa P, Shishkin A, Gankin Y, Kirpich A. Novel Efficient Multistage Lead Optimization Pipeline Experimentally Validated for DYRK1B Selective Inhibitors. J Med Chem 2022; 65:13784-13792. [PMID: 36239428 PMCID: PMC9619999 DOI: 10.1021/acs.jmedchem.2c00988] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
![]()
In addition to general challenges in drug discovery such as the
identification of lead compounds in time- and cost-effective ways,
specific challenges also exist. Particularly, it is necessary to develop
pharmacological inhibitors that effectively discriminate between closely
related molecular targets. DYRK1B kinase is considered a valuable
target for cancer-specific mono- or combination chemotherapy; however,
the inhibition of its closely related DYRK1A kinase is not beneficial.
Existing inhibitors target both kinases with essentially the same
efficiency, and the unavailability of the DYRK1B crystal structure
makes the discovery of DYRK1B-specific inhibitors even more challenging.
Here, we propose a novel multi-stage compound discovery pipeline aimed
at in silico identification of both potent and selective
small molecules from a large set of initial candidates. The method
uses structure-based docking and ligand-based quantitative structure–activity
relationship modeling. This approach allowed us to identify lead and
runner-up small-molecule compounds targeting DYRK1B with high efficiency
and specificity.
Collapse
Affiliation(s)
- Vadim Alexandrov
- Liquid Algo LLC, Hopewell Junction, New York12533, United States
| | - Maria Vilenchik
- Felicitex Therapeutics, Natick, Massachusetts01760, United States
| | - Omar Kantidze
- Quantori LLC, Cambridge, Massachusetts02142, United States
| | - Nika Tsutskiridze
- Quantori LLC, Cambridge, Massachusetts02142, United States.,Tbilisi State Medical University, Tbilisi0186, Georgia
| | - Daviti Kharchilava
- Quantori LLC, Cambridge, Massachusetts02142, United States.,Tbilisi State Medical University, Tbilisi0186, Georgia
| | - Pema Lhewa
- Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, Georgia30303, United States
| | - Aleksandr Shishkin
- Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, Georgia30303, United States
| | - Yuriy Gankin
- Quantori LLC, Cambridge, Massachusetts02142, United States
| | - Alexander Kirpich
- Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, Georgia30303, United States
| |
Collapse
|